OptimizeRx Q2 Earnings Call Highlights

OptimizeRx NASDAQ: OPRX reported second-quarter fiscal 2026 revenue of $20.5 million, down 30% from $29.2 million a year earlier, while adjusted EBITDA totaled $4.9 million, management said on its earnings call. The company reaffirmed its full-year revenue outlook of $95 million to $100 million and adjusted EBITDA guidance of $21 million to $25 million.

MarketBeat • Aug 13, 2026

OptimizeRx Corporation (OPRX) Q2 2026 Earnings Call Transcript

OptimizeRx Corporation (OPRX) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 12, 2026

OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance

–  Q2 revenue totals $20.5 million–  Q2 net loss and adjusted EBITDA of $(0.7) million and $4.9 million, respectively–  Reaffirms fiscal year 2026 revenue guidance of $95 - $100 million and adjusted EBITDA guidance of $21 - $25 million–  Completed debt refinancing with $35 million traditional banking facility, including $25 million term loan and $10 million undrawn revolver; repaid $8.3 million of principal since inception

GlobeNewsWire • Aug 12, 2026

OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates

OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.24 per share a year ago.

Zacks Investment Research • Aug 12, 2026

OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth

The Company Names Andy D'Silva as the next Chief Financial Officer and Heather Favazza as Chief Accounting Officer effective January 1, 2027

GlobeNewsWire • Aug 12, 2026

OptimizeRx Sets Second Quarter 2026 Conference Call for August 12, 2026, at 4:30 p.m. ET

WALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at the most important decision points, will hold a conference call on Wednesday, August 12, 2026, at 4:30 p.m.

GlobeNewsWire • Jul 29, 2026

OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing Officer

WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at key decision moments, today announced the appointment of Sarah Bast as Chief Marketing Officer.

GlobeNewsWire • Jul 23, 2026

OptimizeRx Launches CopayCue™, a Next-Generation Copay Activation Solution Powered by Real-Time Prescribing Intent

Enhanced technology delivers brand savings offers directly within the prescribing workflow, when HCP intent is highest Enhanced technology delivers brand savings offers directly within the prescribing workflow, when HCP intent is highest

GlobeNewsWire • Jun 30, 2026

OptimizeRx Launches Natural Language Audience Builder for Life Sciences DSPs and Agency Media Planning Platforms

Patent-pending, embeddable NLAB technology enables pharma and agency marketers to build custom, verified HCP audiences using natural-language prompts Patent-pending, embeddable NLAB technology enables pharma and agency marketers to build custom, verified HCP audiences using natural-language prompts

GlobeNewsWire • Jun 25, 2026

OptimizeRx to Participate in Upcoming Investor Conferences

WALTHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences:

GlobeNewsWire • Jun 1, 2026